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Deﬁnitive radiotherapy for T2 glottic carcinoma: Experience in our institution
M. Toledo Serrano, A. Román Jobacho, I. Zapata, J. Gomez-Millan, J. Medina Carmona
Hospital Virgen de la Victoria, Oncologia Radioterapica
Introduction. There is a wide range of locoregional control described in the literature regarding T2 glottic carcinoma treated with
deﬁnitive radiotherapy. Identiﬁcation of prognostic factors is needed to increase the therapeutic index of these tumours.
Purpose. To report our experience of deﬁnitive radiotherapy for T2 glottic carcinoma referred to our center between March 2005
and December 2012. Prognostic factors for locoregional recurrence are analyzed.
Method. We retrospectively reviewed the medical records of 37 consecutive patients with T2 glottic carcinoma treated with
Radiotherapy in our Department. Clinical outcome in terms of locoregional control (LRC), disease free survival (DFS) and site of
relapse were evaluated. The prognostic signiﬁcance of different clinical characteristics was analyzed.
Results. 20 patients presented a T2a and 17 a T2b stage. 25 patients were treated with 70Gy/2Gy, 12 patients were treated with
65.25Gy/2.25Gy. Treatment volume included cervical nodes (II–IV) in 7 patients. After a median follow up period of 76 months,
the 5-year DFS was 76.4%. 30% of patients presented a locoregional recurrence (6 local and 1 regional). There was no signiﬁcant
difference in relapse between T2a and T2b. A non signiﬁcant increase in survival was observed in treatment with fractions >2Gy.
In 67.6% of cases the voice quality improved or remained the same after treatment. Acute or chronic toxicity was none or mild
in all cases (only 1 patient had chronic laryngeal edema).
Conclusion. Our results are consistentwith the literature. Only 1 regional recurrencewas observed.Acute side effectswere tolerable
and only 1 patient present chronic laryngeal edema. More patients need to be included to identify signiﬁcant prognostic factors.
http://dx.doi.org/10.1016/j.rpor.2013.03.261
Experience in the radiotherapy treatment of head and neck cancer patients (HNCP) using gastrostomy
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Introduction. The use of gastrostomy as a feeding support in themultimodalmanagement of HNCP receiving radiotherapy remains
controversial.
Objetive. Assess treatment interruption according to the use of gastrostomy.
Methods. Analysis of 210 HNCP that have been irradiated at our Institution with adjuvant or radical radiotherapy between
November 2007 and November 2012.
Results. According to location, there were 12 (5.7%) nasal cavity and sinuses tumors, 42 (20%) oral cavity tumors, 64 (30.6%)
pharyngeal tumors, 17(8%) salivary gland tumors and 75 (35.7%) laryngeal tumors. Gastrostomy was not used in 55 patients with
nasal cavity and sinuses tumors, early laryngeal tumors, salivary gland tumors and patients treated with radiotherapy alone.
From the 130 remaining patients gastrostomy was used in 65.4% (85/130) and refused mainly by the patient in the 34.6% (45/130).
From the 85 patients with gastrostomy, 87.1% (74/85) completed treatment with no interruptions, 10.6% (9/85) completed with
interruptions and 2.4% (2/85) did not complete it. The 15.3% (13/85) required hospitalization. From the remaining 45 patients
without gastrostomy, 77.8% (35/45) completed without interruptions, 13.3% (6/45) completed with interruptions and 8.9% (4/45)
did not complete. The 20% (9/45) required hospitalization.
Conclusion. We could not ﬁnd any statistical differences in the number of interruptions between both groups due to the samples
were not balanced. We recommend gastrostomy in QT-RT radical treatments in pharyngeal, oral cavity and locally advanced
laryngeal cancer patients with very low interruptions and hospitalizations.
http://dx.doi.org/10.1016/j.rpor.2013.03.262
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Resumen
Introduction. Extramedullary plasmocytoma (EMP) is a rare plasmatic cell neoplasia described in soft tissue outside the bone
marrow. The locations more often involved are the submucous and lymphoid tissue of the nose and the paranasal sinuses.
It represents <1% of all the malignant neoplasms of head and neck. When suspected, it must be differentiated from multiple
myeloma. This, sometimes, is difﬁcult, because some of them are associated later on with the development of multiple myeloma.
Objective. We describe two cases of EMP in the nasal cavity. We discuss and review the literature.
Method. (1) Male, 55 years old, with a 6 months history of epistaxis and rhinitis symptoms. The physical examination revealed a
lesion in right nasal cavity, conﬁrmed by scanner. The histopathologic diagnosis was EMP CD138+. He was treated with radiother-
aphy, 45Gy in 25 sessions. (2) Male, 68 years old, also with epistaxis. The physical examination revealed a tumour in nasal septum
that was biopsied with the suspicion of granuloma. The histopathologic diagnosis was plasmocytoma, and the haematologic
